Breaking News: Scientists have started to roll the ball that the T-cells of our immune system are culpable for the protection against corona virus.
A study was published in a journal, namely Nature, spell out the role of antibodies and immune cells in protection against SARS-CoV-2 that causes COVID-19.
Dan Barouch, co-author at Beth Israel Deaconess Medical Center (BIDMC), stances that- “we define the role of antibodies versus T cells in protection against COVID-19 in monkeys. We report that a relatively low antibody titre- the concentration of antibodies in the blood- is needed for protection.”
Mr. Barouch furthered that- “Such knowledge will be important in the development of next generation vaccines, antibody-based therapeutics, and public health strategies for COVID-19.”
Barouch and his colleagues- galvanized by the earlier made studies that claimed that SARS-CoV-2 infection protects rhesus macaques from re exposure- following that, the researchers studied that ‘the collected antibodies from monkeys that had recovered from infection.’
They further pulled the wires that- the antibodies at diversified concentrations to 12 uninfected macaques. Proceeding that, they observed that ‘the protection against SARS-CoV-2 was dosage susceptible.’
According to the researchers, animals that received larger chunks of antibodies were more protected, in comparison with the animals that received smaller amounts.
Similarly, the monkeys testing positive with SARS-CoV-2 infection, were given larger doses manifested more rapid viral control.
In another experiment, the scientists studied the role of specific immune cells, namely CD8 T cells, in being a helping hand towards the protection against the virus.
On the removal of these immune cells, the animals stand at the stage of being thin-skinned to the infection after re-exposure.
Well said by Mr. Barouch, “Our data defines the role of antibodies and T cells in protection against COVID-19 in monkeys. Antibodies alone can protect, including at relatively low levels, but T cells are also helpful if antibody levels are insufficient.”
He furthered, “Such correlates of protection are important given the recent successful vaccine results from human trials, and the likelihood that these and other vaccines will become widely available in the spring.”
Barouch truly suggested that the upcoming vaccines may need to be accredited based on the immunity ties rather than clinical efficacy.
